EMA Details Trial Misconduct Behind Tavneos EU Revocation
The European Medicines Agency published its scientific reasoning for revoking the European marketing authorization of Amgen’s avacopan (Tavneos), citing serious breaches of clinical trial conduct in the drug’s pivotal study—including unblinded access to efficacy…
